BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 33839580)

  • 1. In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC).
    Wang Y; Zhou Y; Cao S; Sun Y; Dong Z; Li C; Wang H; Yao Y; Yu H; Song X; Li M; Wang J; Wei M; Yang G; Yang C
    Bioorg Chem; 2021 Jun; 111():104833. PubMed ID: 33839580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
    Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
    Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
    Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
    Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1.
    Cheng B; Ren Y; Cao H; Chen J
    Eur J Med Chem; 2020 Aug; 199():112377. PubMed ID: 32388281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors.
    Zhang M; Liu J; Wang Y; Wang P; Morris-Natschke S; Lee KH
    Bioorg Med Chem; 2022 Jan; 54():116579. PubMed ID: 34954618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.
    Zhang Y; Yin F; Luo Z; Li S; Li X; Wan S; Chen Y; Kong L; Wang X
    Eur J Med Chem; 2024 May; 271():116433. PubMed ID: 38678826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold.
    Chen H; Wang K; Yang Y; Huang X; Dai X; Feng Z
    Eur J Med Chem; 2021 May; 217():113377. PubMed ID: 33770574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy.
    Ren X; Wang L; Liu L; Liu J
    Front Immunol; 2024; 15():1392546. PubMed ID: 38638430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship and biological evaluation of 12 N-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway.
    Zeng QX; Wang K; Zhang X; Shi YL; Dou YY; Guo ZH; Zhang XT; Zhang N; Deng HB; Li YH; Song DQ
    Bioorg Chem; 2021 Dec; 117():105432. PubMed ID: 34678602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
    Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
    Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti-tumor immunity in non-small cell lung cancer.
    Wang K; Zhou H
    Drug Dev Res; 2021 May; 82(3):422-429. PubMed ID: 33231319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells.
    Wudtiwai B; Makeudom A; Krisanaprakornkit S; Pothacharoen P; Kongtawelert P
    Molecules; 2021 Sep; 26(17):. PubMed ID: 34500779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse.
    Ashizawa T; Iizuka A; Tanaka E; Kondou R; Miyata H; Maeda C; Sugino T; Yamaguchi K; Ando T; Ishikawa Y; Ito M; Akiyama Y
    Biomed Res; 2019; 40(6):243-250. PubMed ID: 31839668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
    Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
    J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 4-Arylindolines Containing a Thiazole Moiety as Potential Antitumor Agents Inhibiting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.
    Qin M; Meng Y; Yang H; Liu L; Zhang H; Wang S; Liu C; Wu X; Wu D; Tian Y; Hou Y; Zhao Y; Liu Y; Xu C; Wang L
    J Med Chem; 2021 May; 64(9):5519-5534. PubMed ID: 33938739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo.
    Guo J; Luo L; Wang Z; Hu N; Wang W; Xie F; Liang E; Yan X; Xiao J; Li S
    J Med Chem; 2020 Nov; 63(22):13825-13850. PubMed ID: 33186040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
    Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
    Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
    Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
    Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Fang L; Tian J; Zhang K; Zhang X; Liu Y; Cheng Z; Zhou J; Zhang H
    Bioorg Med Chem; 2021 Sep; 46():116370. PubMed ID: 34481337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.